Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Paul Ioannidis"'
Autor:
Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to
Externí odkaz:
https://doaj.org/article/cdb9715afd524889a7ec2954a02ff624
Autor:
Mercedes Dávalos-Salas, Magdalene K. Montgomery, Camilla M. Reehorst, Rebecca Nightingale, Irvin Ng, Holly Anderton, Sheren Al-Obaidi, Analia Lesmana, Cameron M. Scott, Paul Ioannidis, Hina Kalra, Shivakumar Keerthikumar, Lars Tögel, Angela Rigopoulos, Sylvia J. Gong, David S. Williams, Prusoth Yoganantharaja, Kim Bell-Anderson, Suresh Mathivanan, Yann Gibert, Scott Hiebert, Andrew M. Scott, Matthew J. Watt, John M. Mariadason
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Histone deacetylase 3 (HDAC3) is a regulator of lipid homeostasis in several tissues, however, its role in intestinal lipid metabolism was not yet known. Here the authors study intestine specific HDAC3 knock out mice and report that these animals hav
Externí odkaz:
https://doaj.org/article/517f7ab37ce74aff9258c9ede119de9a
Autor:
Candani S. A. Tutuka, Miles C. Andrews, John M. Mariadason, Paul Ioannidis, Christopher Hudson, Jonathan Cebon, Andreas Behren
Publikováno v:
Molecular Cancer, Vol 16, Iss 1, Pp 1-5 (2017)
Abstract BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway. This can result in the
Externí odkaz:
https://doaj.org/article/52659a72efb14eaba7327e7008ad3690
Autor:
John M. Mariadason, Amardeep S. Dhillon, Walter D. Fairlie, Erinna F. Lee, Guillaume Lessene, Bryan R.G. Williams, Matthew R. Thompson, Rebecca Nightingale, Mercedes Davalos-Salas, Ian Luk, BeeShin Tan, Lars Togel, Laura Jenkins, Paul Ioannidis, Michael Dickinson, Janson W.T. Tse, Anderly C. Chüeh
Supplementary Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e2f9482eaf569450d0d778f38ced8ea
https://doi.org/10.1158/1078-0432.22467714.v1
https://doi.org/10.1158/1078-0432.22467714.v1
Autor:
John M. Mariadason, Amardeep S. Dhillon, Walter D. Fairlie, Erinna F. Lee, Guillaume Lessene, Bryan R.G. Williams, Matthew R. Thompson, Rebecca Nightingale, Mercedes Davalos-Salas, Ian Luk, BeeShin Tan, Lars Togel, Laura Jenkins, Paul Ioannidis, Michael Dickinson, Janson W.T. Tse, Anderly C. Chüeh
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8119dff03d06bb942c4a75ea1e10da6e
https://doi.org/10.1158/1078-0432.22467717
https://doi.org/10.1158/1078-0432.22467717
Autor:
John M. Mariadason, Amardeep S. Dhillon, Walter D. Fairlie, Erinna F. Lee, Guillaume Lessene, Bryan R.G. Williams, Matthew R. Thompson, Rebecca Nightingale, Mercedes Davalos-Salas, Ian Luk, BeeShin Tan, Lars Togel, Laura Jenkins, Paul Ioannidis, Michael Dickinson, Janson W.T. Tse, Anderly C. Chüeh
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a80380d0f0799727aba65883adfce9
https://doi.org/10.1158/1078-0432.22467720.v1
https://doi.org/10.1158/1078-0432.22467720.v1
Autor:
John M. Mariadason, Amardeep S. Dhillon, Walter D. Fairlie, Erinna F. Lee, Guillaume Lessene, Bryan R.G. Williams, Matthew R. Thompson, Rebecca Nightingale, Mercedes Davalos-Salas, Ian Luk, BeeShin Tan, Lars Togel, Laura Jenkins, Paul Ioannidis, Michael Dickinson, Janson W.T. Tse, Anderly C. Chüeh
Purpose: Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in acute myelogenous leukemia, non–s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575169ec4205135dd1b3ba502efe28f1
https://doi.org/10.1158/1078-0432.c.6526725.v1
https://doi.org/10.1158/1078-0432.c.6526725.v1
Autor:
Austen Lavis, Margeaux Hodgson-Garms, John M. Mariadason, Natalia Vukelic, Paul Ioannidis, Andrew Weickhardt, David K. Lau, Laura J. Jenkins, Ian Y. Luk
Publikováno v:
BMC cancer. 22(1)
Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eae8041b4bfc614c151c78408ba4ef54
https://pubmed.ncbi.nlm.nih.gov/35501832
https://pubmed.ncbi.nlm.nih.gov/35501832
Autor:
David K. Lau, John M. Mariadason, Laura M. Jenkins, Andrew Weickhardt, Margeaux Hodgson-Garms, Natalia Vukelic, Austen Lavis, Ian Luk, Paul Ioannidis
BackgroundMutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10-20% of metastatic urothelial carcinomas, and can confer sensitivity to FGFR inhibitors such as BGJ398 and erdafitinib. However, responses to these agents are o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a28d37d5f58e2b24107906855f1e545
https://doi.org/10.21203/rs.3.rs-142420/v1
https://doi.org/10.21203/rs.3.rs-142420/v1
Autor:
Ian Luk, John M. Mariadason, Anderly C. Chueh, Amardeep S. Dhillon, Matthew R. Thompson, Bee Shin Tan, Janson W.T. Tse, Bryan R.G. Williams, Erinna F. Lee, Lars Tögel, Rebecca Nightingale, Michael Dickinson, Laura J. Jenkins, Mercedes Dávalos-Salas, Guillaume Lessene, W.D. Fairlie, Paul Ioannidis
Publikováno v:
Clinical Cancer Research. 23:5573-5584
Purpose: Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in acute myelogenous leukemia, non–s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e44ed29e7ce202e369a7348bcb4bd429
https://doi.org/10.1158/1078-0432.ccr-17-0466
https://doi.org/10.1158/1078-0432.ccr-17-0466